The neuropsychiatry of movement disorders

Current Opinion in Psychiatry

Volumn 16, Issue 3, 2003, Pages 333-336

  Lennox, Belinda ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Huntington's disease; Obsessive compulsive disorder; PANDAS; Parkinson's disease; Tardive dyskinesia

Indexed keywords

APATHY; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE ASSOCIATION; GILLES DE LA TOURETTE SYNDROME; HUNTINGTON CHOREA; IRRITABILITY; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROPSYCHIATRY; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; STREPTOCOCCUS GROUP A; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY;

EID: 0038742852     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200305000-00010     Document Type: Review

References (33)

1. Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360:397-405. This is a review of the evidence for the biological nature of OCD.
2. Hanna GL, Piacentini J, Cantwell DP, et al. Obsessive-compulsive disorder with and without tics in a clinical sample of children and adolescents. Depress Anxiety 2002; 16:59-63. Patients with OCD were assessed to see whether those with a history of tics could be discriminated from those without. Compulsive behaviours were more common in those without tics.
3. Lin H, Yeh CB, Peterson BS, et al. Assessment of symptom exacerbations in a longitudinal study of children with Tourette's syndrome or obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2002; 41:1070-1077. Significant covariation was shown between severity of OCD and tics in a prospective study of 64 children.
4. Cavallaro R, Galardi G, Cavallini M, et al. Obsessive compulsive disorder among idiopathic focal dystonia patients: an epidemiological and family study. Biol Psychiatry 2002; 52:356-361. Seventy-six patients with idiopathic focal dystonia were examined: 19.7% had OCD, as did 13.8% of first-degree relatives, indicating a shared pathophysiology.
5. Hoekstra PJ, Kallenberg CGM, Koff J, Minderaa RB. Is Tourette's syndrome an autoimmune disease? Mol Psychiatry 2002; 7:437-445. This provides an overview of the current evidence on the existence of PANDAS.
6. Arnold PD, Richter MA. Is obsessive-compulsive disorder an autoimmune disease? CMAJ 2001; 165: 1353-1358.
7. Kurlan R, Como PG, Miller B, et al. The behavioral spectrum of tic disorders: a community based study. Neurology 2002; 59:414-420. Of 1596 schoolchildren interviewed, 339 were found to have tics. When those with and without tics were compared, highly significant associations were found with tics and attention deficit hyperactivity disorder, OCD and anxiety disorders.
8. Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med 2002; 156:356-361. Twelve patients with acute-onset OCD and pharyngitis, with positive throat swabs for group A β-haemolytic streptococcal infection. The use of antibiotics at the sentinel episode eradicated the OCD symptoms. There was recurrence of OCD in six patients, again associated with positive swabs for acute group A β-haemolytic streptococcal infection, and again OCD was successfully treated with antibiotics.
9. Dale RC, Church A J, Cardoso F, et al. Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 2001; 50:588-595.
10. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 2002; 7:617-625. Transgenic mice engineered for glutamatergic excitation of orbitofrontal, limbic and efferent striatal circuitry exhibited OCD-like behaviours and juvenile-onset tics, which responded to clonidine. These data suggest a shared cortical-limbic glutamatergic basis for OCD and tics.
11. Leentjens AFG, Lousberg R, Verhey FRJ. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:196-201. Logistic regression was performed on data from 161 patients with Parkinson's disease, 40 of which also had depression, to explore general and disease-specific risk factors. General risk factors predicted depression, particularly a family history of depression. Right-side onset was illness-variable only to improve the fit of the model.
12. Okun MS, Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology 2002; 58 (Suppl 1):S63-S70.
13. Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 2002; 106:202-211.
14. Schuurman AG, van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58:1501-1504. All subjects over age 20 diagnosed with depression from 1975-1990 in South Netherlands were identified from a general practice database and followed through to 2000; they were matched with a reference group of the same age but who had never been depressed. The hazard ratio for developing Parkinson's disease after depression was 3.13. This study, though retrospective and based on non-expert classifications, provides clear evidence for the prodromal presence of depression in Parkinson's disease.
15. Serra-Mestres J, Ring HA. Evidence supporting a cognitive model of depression in Parkinson's disease. J Nerv Ment Dis 2002; 190:407-410. Non-depressed patients with Parkinson's disease performed worse than matched controls on the Emotional Stroop task, with greater interference to sad words, indicating a possible vulnerability to negative stimuli, and a proneness to depression.
16. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59:408-413. A structured questionnaire was given to 50 patients with fluctuating motor symptoms of Parkinson's disease to monitor for cognitive, psychiatric and dysautonomic symptoms. All reported non-motor fluctuations in association with motor fluctuations, with anxiety (66%), drenching sweats (64%), slowness of thinking (58%) and fatigue (56%) being very common; 28% reported that the non-motor fluctuations were more disabling than the motor fluctuations.
17. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59:1427-1429. Twenty-four patients were studied prospectively for mood changes during deep brain stimulation for refractory Parkinson's disease; 25% experienced depressed mood, and half of these were transiently suicidal, despite the improvement in motor function in all of them.
18. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002; 59:1421-1424. This paper presents three case reports of mania lasting 10-12 days following implantation of subthalamic electrodes for Parkinson's disease.
19. Romito LMA, Scerrati M, Contarino MF, et al. Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology 2002; 58:1546-1550. Follow-up, for 1 to 3 years, of 22 patients after implantation of subthalamic electrodes. Intraoperative psychosis was noted in seven patients, transient mania in two, and worsening of depression in two.
20. Schuurman PR, Bruins J, Merkus MP, et al. A comparison of neuropsychological effects of thalamotomy and thalamic stimulation. Neurology 2002; 59:1232-1239. A prospective follow-up of 62 patients, showing very little effect of either thalamotomy or thalamic stimulation on cognitive testing.
21. Mallet L, Mesnage V, Houeto JL, et al. Compulsions, Parkinson's disease, and stimulation. Lancet 2002; 360:1302-1304. Two patients with Parkinson's disease and severe OCD are described, Subthalamic electrodes were implanted, with improvement in parkinsonism and obsessive symptoms in both cases.
22. Harding AJ, Stimson E, Henderson JM, Halliday GM, Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125:2431-2445. This paper describes the amygdala pathology of 18 non-demented patients with Parkinson's disease who had been prospectively followed up. Lewy bodies in the basolateral nucleus of the amygdala correlated with a history of visual hallucinations.
23. Quinn J, Meagher D, Murphy P, et al. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophr Res 2001; 49:79-87.
24. Lerer B, Segman R, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27:106-119. A meta-analysis of studies published to date on the association of candidate gene DRD3 with tardive dyskinesia. A small overall association was shown, with an odds ratio of 1.33.
25. Zhang Z-J, Zhang X-B, Sha W-W, et al. Association of a polymorphism in the promotor region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7:670-671.
26. Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of 5-HT6 receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002; 110:96-102. No association between polymorphisms of the 5-HT6 gene and tardive dyskinesia was found in a population of 173 Japanese patients with schizophrenia.
27. McCormick SE, Stoessl AJ. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience 2002; 112:851-859.
28. Ohmori O, Shinkai T, Hori H, et al. Polymorphisms of μ and δ opioid receptor genes and tardive dyskinesia in patients with schizophrenia. Schizophr Res 2001; 52:137-138.
29. Zhang Z-J, Zhang X-B, Hou G, et al. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002; 36:317-324.
30. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosug Psychiatr 2001; 71:310-314.
31. Kirkwood SC, Siemers E, Viken R, et al. Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry, Neuropsychol Behav Neurol 2002; 15:192-197. Gene-carriers and non-carriers were tested twice over 3.7 years, before the onset of any motor symptoms. Gene-carriers showed a greater increase in measures of irritability over this period.
32. Berrios GE, Wagle AC, Markova IS, et al. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand 2002; 105:224-230. Pre-symptomatic gene-carriers and non-carriers were compared using a range of psychometric tests. Gene-carriers had significantly worse recognition memory and higher measures of irritability.
33. Thompson JC, Snowden JS, Craufurd D, Neary D. Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 2002; 14:37-43. A cross-sectional study of 82 patients with Huntington's disease, using problembehaviour assessment and disease severity. They found a strong correlation between apathy and cognition and motor function, but mood-based changes of irritability and depression were not correlated with motor function.